News
Updates: Lilly's Global COVID-19 Response
View Story
Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization
View Story
Time to Tear Down the Rebate Wall
View Story
When the World Called for Help with COVID-19, We Were Ready
View Story
Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody
View Story
An Update on Lilly’s Commitment to Quality Manufacturing
View Story
November 24, 2020
Tags | Financial
INDIANAPOLIS , Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a
November 20, 2020
Tags | Product
- Bamlanivimab emerged from collaboration between Lilly and Vancouver-based AbCellera INDIANAPOLIS , Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use
November 20, 2020
Tags | Corporate
Research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets; lead program focused on Duchenne Muscular Dystrophy Precision will receive $100 million cash upfront and an equity investment by Lilly of $35
November 19, 2020
Tags | Product
- ACTT-2 data serve as basis for EUA, the second COVID-19 authorization for a Lilly treatment - Authorization enables use of baricitinib in combination with remdesivir in hospitalized patients needing oxygen INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and